Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics, a clinical-stage biotech firm, has successfully listed on the ASX and raised $6.5 million to advance its clinical trials, including a groundbreaking IV-infused psilocin treatment aimed at addressing the limitations of oral psilocybin. The company has appointed industry experts to guide product registration and reimbursement strategies and renewed the term of a leading psychedelics researcher, Dr. Robin Carhart-Harris, as Chair of their Scientific Advisory Board.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.